Medical Article

Congressional Democrats are seeking to repeal the controversial WISeR model, but experts are unsure if their efforts will succeed. The post Is It Likely That the WISeR Model Will be Repealed? appeared first on MedCity News.

America funds the crisis. It’s time to fund the care that prevents it. The post Dying Without a Safety Net appeared first on MedCity News.

We do not need models that pretend every patient has equal or equitable access to care. We need models capable of recognizing disparities and responding to them. The post Is Bias in Clinical AI Good or Bad? It’s More Complicated Than That appeared first on MedCity News.

AI will continue changing how small molecules are discovered, but the candidates that generate the most interest in silico still have to succeed under real development conditions. The post AI Can Accelerate Discovery — Development Still Decides What Advances appeared first on MedCity News.

Today’s adjustment offers insight into what the next phase of the program is focusing on and will subsequently reward, and why this moment matters, especially for newer and regional plans. The post Medicare Advantage’s Big Decision: Reset or Retreat? appeared first on MedCity News.

Through a new partnership, Marathon employer clients who don’t currently offer Lantern’s specialty care benefit can purchase it directly through Marathon. The post Lantern, Marathon Health Launch Partnership to Provide Integrated Primary and Specialty Care appeared first on MedCity News.

Kardigan was able to upsize its IPO, raising more cash for three drug candidates in mid-stage clinical development for cardiovascular conditions with no available therapies. All three programs are expected to report key data in 2027 that could pave the way for Phase 3 testing. The post Kardigan’s IPO Lands $400M for Drugs That Get…

A recent JAMA editorial from two radiologists argues that elective whole-body MRI scan companies are misleading consumers about the benefits of said scans. The radiologists argue the MRIs are more likely to trigger harmful downstream procedures than they are to save lives. Not surprisingly, the three most prominent companies offering these scans denied the charge….

These structures, if not set up and managed correctly from day one, can create significant accounting, tax and compliance headaches down the road. The post What Life Sciences Companies Get Wrong When Building Cross-Border R&D Structures appeared first on MedCity News.